Study of rocuronium onset time shortened

Study of rocuronium onset time shortened - Study of rocuronium onset time shortened

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020599

Enrollment

Registered

2016-01-18

Start date

2016-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General anesthesia target disease

Interventions

Control group: rocuronium 0.6 mg / kg after the administration, to boost over a 5 mL saline 4 seconds. Saline 20 mL groups: rocuronium 0.6 mg / kg after the administration, and to boost the 20 mL sali

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Tracheal intubation in our hospital operating room, those undergoing surgery under general anesthesia. Adult men and women 90 patients. Non-elderly group 45 patients, the elderly group of 45 patients. ASA-PS1-2(those without systemic disease, or those with mild systemic disease)

Exclusion criteria

Exclusion criteria: Patients with neuromuscular disorders. Patients with drugs that interaction with muscle relaxant. Patient of NYHA3 more. BMI 25 greater, or 18.5 less of patients. Chronic renal failure or patient that has been introduced an artificial dialysis. Cirrhosis patient.

Design outcomes

Primary

Measure	Time frame
Shortening of the muscle relaxant effect expression time	—

Countries

Japan

Contacts

Public ContactHiromasa Kida

Kanazawa medical university Anesthesiology

kida0430@kanazawa-med.ac.jp076-286-3511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026